Patents by Inventor Claudia Karl

Claudia Karl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230346780
    Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.
    Type: Application
    Filed: May 4, 2023
    Publication date: November 2, 2023
    Inventors: Michael Karl Bechtold, Julie Kay Cahill, Katja Maren Fastnacht, Kieran James Lennon, Bernd Harald Liepold, Claudia Bettina Packhaeuser, Benedikt Steitz
  • Publication number: 20230338372
    Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.
    Type: Application
    Filed: May 4, 2023
    Publication date: October 26, 2023
    Inventors: Michael Karl Bechtold, Julie Kay Cahill, Katja Maren Fastnacht, Kieran James Lennon, Bernd Harald Liepold, Claudia Bettina Packhaeuser, Benedikt Steitz
  • Publication number: 20230288402
    Abstract: The present invention relates to a method for identifying a pharmaceutically active compound that modulates the rpL35 (rpL35/rpL29)-dependent translation of at least one mRNA in a mammalian cell. The mRNA may comprise a premature termination codon (PTC), undergoes premature translation termination, causes programmed ?1 ribosomal frame shifting (?1PRF), or is a polycistronic mRNA. Furthermore a respective screening system, methods of treating or preventing a disease or condition, and compounds that modulate the rpL35 (rpL35/rpL29)-dependent translation, in particular atazanavir or derivatives thereof and artemisinin or artesunate or derivatives thereof are provided.
    Type: Application
    Filed: July 30, 2021
    Publication date: September 14, 2023
    Inventors: HANNELORE BREITENBACH-KOLLER, JÖRG VON HAGEN, HELMUT HINTNER, FRIEDRICH LOTTSPEICH, HANS-WERNER MEWES, NORBERT MÜLLER, ANDREAS FRIEDRICH, KATHARINA ELSENSOHN, CLAUDIA MOSSHAMMER, MICHAEL WIESSNER, THOMAS KARL, JAN SCHERNTHANER, ADRIANA RATHNER
  • Patent number: 8841430
    Abstract: The present invention relates to the use of regulatory sequences for mediating specific, early transient expression in proliverative neuronal determined cells. Furthermore, the uses of recombinant nucleic acid molecules comprising said defined regulatory sequences for mediating specific, early transient expression in proliverative neuronal determined cells as well as for the generation of non-human transgenic organisms and/or host cells are disclosed. In addition, the invention provides for transgenic non-human animals and/or host cells comprising said regulatory sequences and/or recombinant nucleic acid molecules. The invention also describes methods for the preparation of such vectors, host cells and transgenic non-human animals as well as methods for the detection and/or isolation of neuronal determined cells.
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: September 23, 2014
    Assignee: F. Hoffmann-La Roche Inc.
    Inventors: Sébastien Couillard-Despres, Claudia Karl, Hans-Georg Kuhn, Ludwig Aigner
  • Patent number: 8815505
    Abstract: The present invention relates to the use of regulatory sequences for mediating specific, early transient expression in proliferative neuronal determined cells. Furthermore, the uses of recombinant nucleic acid molecules comprising said defined regulatory sequences for mediating specific, early transient expression in proliferative neuronal determined cells as well as for the generation of non-human transgenic organisms and/or host cells are disclosed. In addition, the invention provides for transgenic non-human animals and/or host cells comprising said regulatory sequences and/or recombinant nucleic acid molecules. The invention also describes methods for the preparation of such vectors, host cells and transgenic non-human animals as well as methods for the detection and/or isolation of neuronal determined cells.
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: August 26, 2014
    Assignee: F. Hoffmann-La Roche Inc.
    Inventors: Sébastien Couillard-Despres, Claudia Karl, Hans-Georg Kuhn, Ludwig Aigner
  • Patent number: 7947448
    Abstract: The present invention relates to the use of regulatory sequences for mediating specific, early transient expression in proliferative neuronal determined cells. Furthermore, the uses of recombinant nucleic acid molecules comprising said defined regulatory sequences for mediating specific, early transient expression in proliferative neuronal determined cells as well as for the generation of non-human transgenic organisms and/or host cells are disclosed. In addition, the invention provides for transgenic non-human animals and/or host cells comprising said regulatory sequences and/or recombinant nucleic acid molecules. The invention also describes methods for the preparation of such vectors, host cells and transgenic non-human animals as well as methods for the detection and/or isolation of neuronal determined cells.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: May 24, 2011
    Assignee: F. Hoffmann-La Roche Inc.
    Inventors: Sebastien Couillard-Despres, Claudia Karl, Hans-Georg Kuhn, Ludwig Aigner
  • Publication number: 20110020790
    Abstract: The present invention relates to the use of regulatory sequences for mediating specific, early transient expression in proliferative neuronal determined cells. Furthermore, the uses of recombinant nucleic acid molecules comprising said defined regulatory sequences for mediating specific, early transient expression in proliferative neuronal determined cells as well as for the generation of non-human transgenic organisms and/or host cells are disclosed. In addition, the invention provides for transgenic non-human animals and/or host cells comprising said regulatory sequences and/or recombinant nucleic acid molecules. The invention also describes methods for the preparation of such vectors, host cells and transgenic non-human animals as well as methods for the detection and/or isolation of neuronal determined cells.
    Type: Application
    Filed: September 30, 2010
    Publication date: January 27, 2011
    Inventors: Sébastien Couillard-Despres, Claudia Karl, Hans-Georg Kuhn, Ludwig Aigner
  • Publication number: 20110016547
    Abstract: The present invention relates to the use of regulatory sequences for mediating specific, early transient expression in proliverative neuronal determined cells. Furthermore, the uses of recombinant nucleic acid molecules comprising said defined regulatory sequences for mediating specific, early transient expression in proliverative neuronal determined cells as well as for the generation of non-human transgenic organisms and/or host cells are disclosed. In addition, the invention provides for transgenic non-human animals and/or host cells comprising said regulatory sequences and/or recombinant nucleic acid molecules. The invention also describes methods for the preparation of such vectors, host cells and transgenic non-human animals as well as methods for the detection and/or isolation of neuronal determined cells.
    Type: Application
    Filed: September 30, 2010
    Publication date: January 20, 2011
    Inventors: Sébastien Couillard-Despres, Claudia Karl, Hans-Georg Kuhn, Ludwig Aigner
  • Publication number: 20090170099
    Abstract: The present invention relates to the use of regulatory sequences for mediating specific, early transient expression in proliferative neuronal determined cells. Furthermore, the uses of recombinant nucleic acid molecules comprising said defined regulatory sequences for mediating specific, early transient expression in proliferative neuronal determined cells as well as for the generation of non-human transgenic organisms and/or host cells are disclosed. In addition, the invention provides for transgenic non-human animals and/or host cells comprising said regulatory sequences and/or recombinant nucleic acid molecules. The invention also describes methods for the preparation of such vectors, host cells and transgenic non-human animals as well as methods for the detection and/or isolation of neuronal determined cells.
    Type: Application
    Filed: September 12, 2008
    Publication date: July 2, 2009
    Inventors: Sebastien COUILLARD-DESPRES, Claudia Karl, Hans-Georg Kuhn, Ludwig Aigner